Weight Loss Medication Guides
In-depth guides to Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, and other GLP-1 medications. Dosing, efficacy, side effects, costs, and how to get started.
Semaglutide
The most widely prescribed GLP-1 medication for weight loss and type 2 diabetes management.
Read full guide →Tirzepatide
The first dual-action GIP/GLP-1 medication, delivering the highest weight loss in clinical trials.
Read full guide →Orforglipron
The first oral GLP-1 that does not require an empty stomach, a 30-minute wait, or a specific time of day. FDA approved April 2026.
Read full guide →Retatrutide
Eli Lilly's investigational triple agonist. Not yet FDA approved. In the TRIUMPH-1 Phase 3 trial, the highest dose produced about 28.3% average weight loss over 80 weeks, the strongest results ever published for a weight loss medication.
Read full guide →CagriSema
Novo Nordisk's once-weekly combination of cagrilintide and semaglutide. Not yet FDA approved. It was filed for review in December 2025 and produced about 22.7% average weight loss in the REDEFINE 1 trial, though it lost a head-to-head trial against Zepbound.
Read full guide →Liraglutide
The first GLP-1 medication approved for weight management, now complemented by newer options.
Read full guide →Brand-Specific Guides
Dedicated guides for the brand names patients search for most.
Foundayo
Eli Lilly's daily weight loss pill, FDA approved April 2026. The first GLP-1 pill that does not require an empty stomach, a 30-minute wait, or a specific time of day.
Read Foundayo guide →Wegovy
Novo Nordisk's weight loss semaglutide, sold as a weekly shot and, since January 2026, a daily pill. Patients in the main clinical trial lost about 15% of their body weight on average, and Wegovy is the only GLP-1 with FDA-approved cardiovascular benefit for people with obesity.
Read Wegovy guide →Ozempic
Novo Nordisk's weekly injection for type 2 diabetes. Ozempic is the most widely prescribed GLP-1 in the world, and the same drug (semaglutide) that is sold as Wegovy for weight loss.
Read Ozempic guide →Mounjaro
Eli Lilly's weekly injection for type 2 diabetes. Mounjaro is the same drug as Zepbound (tirzepatide), but labeled for diabetes rather than weight loss.
Read Mounjaro guide →Zepbound
Eli Lilly's weight loss shot. Patients in the largest clinical trial lost an average of 22.5% of their body weight, the most of any FDA-approved weight loss drug.
Read Zepbound guide →Not Sure Which Medication Is Right for You?
Compare medications head-to-head with clinical trial data.
Ready to get started?
Find a GLP-1 prescriber near you. Search by medication, insurance, and telehealth options.